Known targets — ChEMBL curated mechanism
ABL1BMXBRAFBTKCHRNA4CHRNB2CSNK1EEGFRERBB2F10FLT1FLT3FLT4IGF1RINSRITKJAK3KDRKITOPRM1PARP1PARP2PDGFRBPIK3CDRAF1RETSLC18A2TECTXKdacAdacBdacCftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.48 |
| ▸ | CA1 | P00915 | 5/20 | 0.47 |
| ▸ | CA2 | P00918 | 5/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | AR | P10275 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2536 | 0.88 | LMNA (0.57) | LMNAMAPTALDH1A1CA1CA2 | |
| SCHEMBL8508557 | 0.85 | ALDH1A1 (0.64) | LMNAMAPTALDH1A1CA1CA2 | |
| SCHEMBL4447797 | 0.84 | LMNA (0.54) | LMNAMAPTALDH1A1CA1CA2 | |
| SCHEMBL3654908 | 0.84 | LMNA (0.54) | LMNAMAPTALDH1A1CA1CA2 | |
| SCHEMBL57630 | 0.84 | LMNA (0.62) | LMNAMAPTALDH1A1CA1CA2 | |
| SCHEMBL11660143 | 0.83 | LMNA (0.53) | LMNAMAPTALDH1A1CA1CA2 | |
| SCHEMBL11624179 | 0.83 | LMNA (0.53) | LMNAMAPTALDH1A1CA1CA2 | |
| SCHEMBL1687346 | 0.83 | ALDH1A1 (0.61) | LMNAMAPTALDH1A1KMT2ACYP1A2 | |
| SCHEMBL18281078 | 0.83 | LMNA (0.68) | LMNAMAPTALDH1A1CA1CA2 | |
| SCHEMBL717926 | 0.83 | LMNA (0.68) | LMNAMAPTALDH1A1CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11185594-B2 | (Anti-HER2 antibody)-drug conjugate | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2021-11-30 | — | — | US | disclosed |
| EP-3130608-B1 | (ANTI-HER2 ANTIBODY)-DRUG CONJUGATE | DAIICHI SANKYO CO LTD (JP) | 2019-09-04 | — | — | EP | disclosed |
| EP-3130608-A1 | (ANTI-HER2 ANTIBODY)-DRUG CONJUGATE | Daiichi Sankyo Co., Ltd. (JP) | 2017-02-15 | — | — | EP | disclosed |
| US-20170035906-A1 | (ANTI-HER2 ANTIBODY)-DRUG CONJUGATE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2017-02-09 | — | — | US | disclosed |
| CN-103298778-B | Glycine derivatives having melanogenesis inhibitory activity and whitening compositions containing the same | CORUM INC | 2015-03-25 | — | — | CN | disclosed |
| CN-104257515-A | Glycine derivatives having melanogenesis inhibitory activity and whitening compositions containing the same | CORUM INC | 2015-01-07 | — | — | CN | disclosed |
| EP-1757609-B1 | NOVEL WATER-SOLUBLE PRODRUG | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2013-10-16 | — | — | EP | disclosed |
| CN-103298778-A | Glycine derivatives having melanogenesis inhibitory activity and whitening compositions containing the same | CORUM INC | 2013-09-11 | — | — | CN | disclosed |
| WO-2012051741-A1 | GLYCIN DERIVATIVES INHIBITING MELANIN PRODUCTION AND WHITENING COMPOSITION THEREOF | 新钰生技股份有限公司 (CN) | 2012-04-26 | — | — | WO | disclosed |
| US-8022047-B2 | Combination anticancer agents | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2011-09-20 | — | — | US | disclosed |
| EP-1938823-A1 | AGENT FOR PREVENTING OR TREATING PANCREAS CANCER, OVARY CANCER OR LIVER CANCER CONTAINING NOVEL WATER-SOLUBLE PRODRUG | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2008-07-02 | — | — | EP | disclosed |
| EP-1925309-A1 | NOVEL ANTICANCER CONCOMITANT DRUG | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2008-05-28 | — | — | EP | disclosed |
| US-20080015157-A1 | Novel Water-Soluble Prodrugs | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2008-01-17 | — | — | US | disclosed |
| WO-2007146085-A2 | CREATINE PHOSPHATE PRODRUGS, COMPOSITIONS AND USES THEREOF | XENOPORT, INC. (US) | 2007-12-21 | — | — | WO | disclosed |
| EP-1757609-A1 | NOVEL WATER-SOLUBLE PRODRUG | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2007-02-28 | — | — | EP | disclosed |
| WO-2001027141-A1 | INHIBITORS OF FACTOR XA HAVING AN ARGININE OR ARGININE ALDEHYDE MIMIC | CORVAS INTERNATIONAL, INC. (US) | 2001-04-19 | — | — | WO | disclosed |
| US-6025472-A | PEPTIDE ALDEHYDES WHICH ARE POTENT INHIBITORS OF FACTOR XA, USEFUL AS THERAPEUTIC AGENTS FOR DISEASE STATES IN MAMMALS CHARACTERIZED BY ABNORMAL THROMBOSIS | CORVAS INTERNATIONAL, INC. (US) | 2000-02-15 | — | — | US | disclosed |
| US-5696231-A | ANTICOAGULANTS; CARDIOVASCULAR DISORDERS | CORVAS INTERNATIONAL, INC. (US) | 1997-12-09 | — | — | US | disclosed |
| EP-0801654-A1 | N-SUBSTITUTED GLYCINE DERIVATIVES AS INHIBITORS OF FACTOR Xa | CORVAS INTERNATIONAL, INC. (US) | 1997-10-22 | — | — | EP | disclosed |
| WO-1996019493-A1 | N-SUBSTITUTED GLYCINE DERIVATIVES AS INHIBITORS OF FACTOR Xa | CORVAS INTERNATIONAL, INC. (US) | 1996-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170035906-A1 | (ANTI-HER2 ANTIBODY)-DRUG CONJUGATE | ERBB2, EGFR, LANCL2 | LMNA 139/4885MAPT 836/4885ALDH1A1 2238/4885 |
| US-20080015157-A1 | Novel Water-Soluble Prodrugs | ADH1A, ADH1C, SLC43A1 | LMNA 4344/4885MAPT 3789/4885ALDH1A1 142/4885 |
| US-11185594-B2 | (Anti-HER2 antibody)-drug conjugate | ERBB2, EGFR, LANCL2 | LMNA 139/4885MAPT 836/4885ALDH1A1 2238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.